Call us now:
Advancing Biologic Therapies for Critical Medical Needs
Therapeutic Products
RyGen Biopharma develops innovative therapeutic biologics using advanced recombinant DNA (r-DNA) technology. Our development programs focus on high-impact therapeutic areas where biologic medicines can significantly improve patient outcomes. By combining strong scientific expertise with globally aligned regulatory strategies, we aim to deliver safe, effective, and accessible biologic therapies.
Our therapeutic portfolio targets major disease segments including metabolic disorders, oncology supportive care, autoimmune diseases, bone health, and haematological conditions.
Advancing Biologic Therapies for Critical Medical Needs
Recombinant Enzymes
RyGen Biopharma develops high-quality recombinant enzymes designed for use in biotechnology research, biopharmaceutical development, and industrial bioprocessing. Produced using advanced recombinant DNA technology, our enzymes are engineered to deliver high purity, stability, and consistent performance across a wide range of scientific and manufacturing applications.
Our enzyme portfolio supports critical workflows in protein purification, enzymatic cleavage, analytical studies, and downstream bioprocessing, helping researchers and biopharmaceutical manufacturers achieve reliable and reproducible results.
